Article
Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Oct 2014
Pallaud Celine, Reck Martin, Juhasz Erzsebet, Szima Barna, Yu Chung-Jen, Burdaeva Olga, Orlov Sergey, Hilton Magalie, Archer Venice, Mok Tony
Abstract excerpt
OBJECTIVES: ABIGAIL, a phase II, randomized, open-label, multicenter study evaluated the correlation between biomarkers and best overall response (BOR) to bevacizumab with chemotherapy in patients with advanced or recurrent non-small-cell lung cancer (NSCLC). Exploratory analyses of vascular endothelial growth factor (VEGF) clinical genotyping data are presented. MATERIALS AND METHODS: A total of 303 patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.